Cargando…
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice
INTRODUCTION: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmo...
Autores principales: | Majid, Tabassum, Griffin, Deric, Criss, Zachary, Jarpe, Matthew, Pautler, Robia G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975056/ https://www.ncbi.nlm.nih.gov/pubmed/29854936 http://dx.doi.org/10.1016/j.trci.2015.08.001 |
Ejemplares similares
-
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2019) -
Recovering a sense of reality
por: Gross, Michael
Publicado: (2021) -
How does paediatric dentistry recover post-pandemic?
por: Westgarth, David
Publicado: (2021) -
Can antibiotic prescribing recover its downward trajectory during 2021?
por: Sanderson, Susie, et al.
Publicado: (2021) -
Characterization of a novel MR‐detectable nanoantioxidant that mitigates the recall immune response
por: Inoue, Taeko, et al.
Publicado: (2016)